NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 9.48 against a street estimate of 11.15 — a miss of 15.0%.
with an average price target of ₹1,195.78.
CONFIDENT Zydus delivered 22% revenue growth to INR 80.2B with 24.1% EBITDA margin. India branded formulations grew 20%, U.S. specialty expanded via Assertio acquisition and first biosimilar launch. Guidance maintains double-digit growth and 24%+ EBITDA despite Saroglitazar investment phase. Q1 FY27 India branded outpacing market by 300–500 bps; mid-teens growth expected. U.S. single-digit guidance despite specialty scaling. Emerging and Europe markets delivering growth. U.S. specialty to reach 15%+ by year-end. Analysts pressed sustainability of India 20% growth (confirmed chronic/biosimilar-driven, not semaglutide-led) and Saroglitazar commercialization timeline/peak sales (management guided 2-year investment phase post-April FY '28 launch, INR 200–400M peak range). U.S. single-digit guidance questioned but affirmed despite specialty scaling; FY '28 expected to show improvement. 2026-0…
Full summary in the app.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 ZYDUS LIFESCIENCES LIMITED – INVESTOR SUMMARY August 2026 Corporate Presentation --- HEADLINE NUMBERS • FY26 Revenue: US$ 3.02 billion (INR 271,484 | 2026-08-23 |
| Q1 FY27 earnings call ZYDUS LIFESCIENCES LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Consolidated Revenue: ₹80.2 billion, up 22% year-on-year • EBITDA: ₹19 | 2026-08-18 |
| Quarterly results · Q1 FY27 ZYDUS LIFESCIENCES LIMITED – Q1 FY2027 RESULTS SUMMARY HEADLINE NUMBERS STANDALONE (Parent Company Only) • Revenue from operations Q1 FY27: INR 28,7 | 2026-08-11 |
| Investor presentation | 2026-08-11 |
| Annual report FY2026 ZYDUS LIFESCIENCES LIMITED – ANNUAL REPORT FY2025-26 SUMMARY HEADLINE NUMBERS • Consolidated Revenue: ₹271.5 billion, growth of 17% year-over-year • | 2026-07-10 |
| Q4 FY26 earnings call ZYDUS LIFESCIENCES LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenues FY26: ₹271.5 billion, up 17% year-on-year • Q4 FY26 r | 2026-05-24 |
| Quarterly results · Q4 FY26 ZYDUS LIFESCIENCES LIMITED – FINANCIAL RESULTS SUMMARY For Quarter and Year Ended March 31, 2026 --- HEADLINE NUMBERS • Net Profit (FY 2025-26): IN | 2026-05-19 |
| Investor presentation ZYDUS LIFESCIENCES LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenues (Q4 FY26): Rs. 75,870 mn, up 16% YoY (FY26 full year: Rs. 2,71, | 2026-05-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Jul 24, 2026 | 2026-07-24 |
| Announcement | Date |
|---|---|
| Receives EIR from USFDA for injectable facility with VAI classification Zydus Lifesciences announced that it received an Establishment Inspection Report (EIR) from the US FDA for one of its injectable manufacturing facilities. The facility has been classified wi | 2026-08-01 |
| Joint venture formation in Sri Lanka Zydus Lifesciences Limited has informed the Exchange about Joint Venture in Sri Lanka | 2026-06-26 |
| Successful completion of acquisition of Assertio Holdings Zydus Lifesciences has successfully completed its acquisition of Assertio Holdings, as announced on June 16, 2026. This marks the finalization of a strategic deal that expands Zydus's portfo | 2026-06-16 |
| Share buyback program announced Zydus Lifesciences Limited has informed the Exchange about Buyback | 2026-06-01 |
| Share buyback program announced Zydus Lifesciences Limited has informed the Exchange about Buyback | 2026-06-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zydus Lifesciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.